Analysts Set Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Price Target at $28.00

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have earned a consensus rating of “Reduce” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $28.00.

FMS has been the subject of a number of analyst reports. The Goldman Sachs Group lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Erste Group Bank lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Jefferies Financial Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research report on Tuesday, February 24th. Truist Financial set a $28.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Finally, Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.1%

NYSE FMS opened at $22.77 on Friday. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.94 and a 1-year high of $30.46. The company has a current ratio of 1.26, a quick ratio of 0.92 and a debt-to-equity ratio of 0.40. The stock has a 50-day moving average of $23.13 and a 200-day moving average of $24.30. The firm has a market cap of $13.20 billion, a PE ratio of 11.92, a price-to-earnings-growth ratio of 2.16 and a beta of 0.91.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its earnings results on Tuesday, February 24th. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.16. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $4.80 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.73% and a net margin of 5.03%. As a group, sell-side analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Hedge funds have recently made changes to their positions in the business. Brooklyn Investment Group lifted its stake in Fresenius Medical Care AG & Co. KGaA by 5.4% in the fourth quarter. Brooklyn Investment Group now owns 8,860 shares of the company’s stock worth $212,000 after acquiring an additional 450 shares during the period. GAMMA Investing LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 5.9% during the 3rd quarter. GAMMA Investing LLC now owns 10,437 shares of the company’s stock valued at $275,000 after purchasing an additional 585 shares during the period. Hantz Financial Services Inc. increased its position in Fresenius Medical Care AG & Co. KGaA by 10.5% during the 4th quarter. Hantz Financial Services Inc. now owns 7,370 shares of the company’s stock valued at $176,000 after purchasing an additional 699 shares during the period. Fifth Third Bancorp raised its holdings in Fresenius Medical Care AG & Co. KGaA by 4.0% in the 4th quarter. Fifth Third Bancorp now owns 18,766 shares of the company’s stock worth $447,000 after purchasing an additional 726 shares in the last quarter. Finally, Arax Advisory Partners lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% in the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares during the period. 8.37% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.